Conferences
17–19 January 2012, London, UK
5th Annual Recombinant Antibodies Conference
Louise Holliday will be speaking at Visiongain’s 5th Annual Recombinant Antibodies conference. The conference will allow delegates to:
- Network with key decision makers at leading companies
- Improve the potency of IgG molecules for ADCC, ADCP and CDC applications
- Enhance immune effector functions through targeted Fc region engineering
- Increase in vivo circulation time with conjugated immunoglobulins
- Extend pharmacokinetic half-life and exposure
- Better utilise, deploy and evaluate in silico tools during early-phase research
- Optimise antigen-binding domains
- Engineer decreased immunogenicity, cross-reactivity and in vivo toxicity
- Assess new technologies for selecting antibody attributes
- Maximise site-specific drug loading for bispecific antibodies
- Obtain new data on inflammatory disease, and solid and liquid cancer targets
- Block activation of angiogenic signalling pathways and disrupt the tumour microenvironment
